Sumitomo Chemical India Q1 FY27: Stable revenue, stronger margins, and a clear capex roadmap

Sumitomo Chemical India Limited reported a steady start to FY27 in a quarter where the domestic agrochemical market faced a difficult backdrop. The company highlighted a delayed South West monsoon, a rainfall deficit through June, lower reservoir levels, and a sharp decline in early kharif sowing. Channel inventory overhang and price corrections also weighed on near term demand.

Against this, consolidated revenue from operations rose 1 percent year on year to INR 1,063.3 crore in Q1 FY27. Profitability improved meaningfully. Gross profit increased to INR 416.7 crore and gross margin expanded to 39.2 percent. Operating EBITDA rose to INR 233.3 crore, with EBITDA margin at 21.9 percent. Reported net profit was INR 214.5 crore, supported by an exceptional insurance claim related to the FY23 Bhavnagar plant fire.

A quarter shaped by monsoon delay, but protected by mix and pricing

The company’s commentary makes it clear that domestic demand remained subdued. The early part of the kharif season was impacted by delayed rains and lower acreage, and distributors carried elevated inventory after advance purchases in March and April. Even so, the company delivered a resilient operating outcome through disciplined execution, calibrated price actions in April and May, and a favourable product mix.

Exports provided an important offset. Export revenues grew 26 percent year on year, taking exports to 16 percent of Q1 FY27 sales. Management attributed this to strong growth in South America, Asia excluding India, and Africa, partly offset by lower sales in Japan and North America.

Within the portfolio, metal phosphides and the animal nutrition plus environmental health divisions helped provide resilience, while herbicides, fungicides and plant growth regulators saw softer demand.

Revenue mix: steady core, improving contribution from metal phosphides and allied segments

The Q1 revenue mix remained anchored in insecticides and herbicides. Insecticides were stable at 35 percent of sales, while herbicides moderated to 31 percent from 34 percent last year. Metal phosphides rose to 10 percent from 8 percent, and animal nutrition plus environmental health increased to 13 percent from 11 percent.

This mix matters because the quarter was not a broad based volume growth story. Instead, it was a story of holding revenue steady while improving realization, managing costs, and leaning into segments that were less exposed to the immediate domestic demand slowdown.

The company also disclosed that generic products made up 76 percent of Q1 FY27 revenue, while specialty products were 24 percent. In domestic sales, branded products were 77 percent and bulk was 23 percent. In exports, bulk continued to dominate at 64 percent, with branded at 36 percent.

Working capital: seasonal build shows up, collections remain strong

As expected in a seasonal agrochemical business, working capital moved during the quarter. Net working capital days were 56 in June 2026 compared with 43 in June 2025, primarily due to seasonal inventory build ahead of kharif and higher inventory carrying values. Inventory stood at INR 883.6 crore.

There were offsets. Trade receivable days improved to 68 from 76, which management attributed to disciplined collections and channel control. The company also disclosed collections of about INR 1,178 crore during Q1 FY27.

The company highlighted a strong liquidity position, stating cash and cash equivalents of INR 2,549 crore as of 30 June 2026.

What changed beyond the quarter: capex visibility and leadership transition

Two announcements in the presentation stand out for investors tracking medium term execution.

First, the company reiterated near term commercial momentum initiatives. It referenced annual sales alignment, regional marketing execution meetings, channel engagement, and division wise product prioritization. It also stated that Topgrain and Helibax, a Pyridyl plus Enamectin product, remain on track for launch during Q2 FY27.

Second, it provided a clearer picture of capex projects approved by the board in January 2026. The largest is a Dahej project to manufacture a herbicide intermediate for supply to the parent company, with a capex budget of about INR 150 crore and estimated commercialization in Q2 FY29. A smaller Tarapur fitment project of about INR 10 crore is aimed at manufacturing two additional molecules, one fungicide and one herbicide, primarily for supply to the parent company, with estimated commercialization in Q4 FY28. The presentation states a payback period of less than 5 years from start of operations.

This capex framing is notable because it links investments to a timeline and a payback period, and positions the company as an integrated manufacturing hub within the parent group’s global supply chain.

The presentation also outlined a board and leadership transition effective 1 September 2026. The current managing director’s term ends on 31 August 2026 and he is expected to move to a non executive role. Dr Suresh Ramachandran is to be appointed managing director from 1 September 2026.

Takeaways for investors

Q1 FY27 does not show a demand led upcycle. It shows resilience. Revenue held steady in a weak domestic environment, margins improved through pricing actions and mix, and exports provided meaningful support. Investors should also separate underlying profitability from the reported net profit uplift, since the quarter includes an exceptional insurance claim related to a past incident.

Beyond the quarter, the presentation strengthens the medium term narrative through a clearly timed capex plan at Dahej and Tarapur, an explicit payback statement, and a defined senior leadership transition timeline. The operational environment remains closely tied to monsoon progress and channel inventory dynamics, but the company is positioning itself to reduce volatility through exports, portfolio diversification, and supply chain integration with the parent company.